PT20

A treatment for hyperphosphatemia

PT20 is a treatment for hyperphosphatemia and has successfully completed a first pivotal trial.

In addition, the Group has earlier stage assets that it intends to develop or out-license over time.

PT20 has completed its first pivotal study with one further pivotal Phase 3 study planned in order to seek regulatory approval in major markets.

London, UK

One Euston Square
40 Melton Street
London, NW1 2FD

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Shield Therapeutics
c/o Shield Holdings AG
Sihleggstrasse 23, 8832 Wollerau

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

Shield Therapeutics (DE)
Leopoldstr. 23
80802 M√ľnchen, Germany

einfo@shieldtx.com